Hugel Inc - Asset Resilience Ratio

Latest as of March 2026: 29.57%

Hugel Inc (145020) has an Asset Resilience Ratio of 29.57% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check 145020 PP&E to net assets ratio to assess the company's strategic physical and investment asset allocation.

Liquid Assets

₩335.36 Billion
≈ $227.27 Million USD Cash + Short-term Investments

Total Assets

₩1.13 Trillion
≈ $768.68 Million USD All company assets

Resilience Assessment

Very High
Financial Resilience Level

Asset Resilience Ratio Trend (2014–2025)

This chart shows how Hugel Inc's Asset Resilience Ratio has changed over time. See 145020 net asset quality index to measure how much of total assets are equity-financed.

Liquid Assets Composition Over Time

This chart breaks down Hugel Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see how much is Hugel Inc worth.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents ₩0.00 0%
Short-term Investments ₩335.36 Billion 29.57%
Total Liquid Assets ₩335.36 Billion 29.57%

Asset Resilience Insights

  • Very High Liquidity: Hugel Inc maintains exceptional liquid asset reserves at 29.57% of total assets.
  • This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
  • The company has significant short-term investments, indicating active treasury management.

Hugel Inc Industry Peers by Asset Resilience Ratio

Compare Hugel Inc's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Argen-X
F:1AE
Biotechnology 10.93%
CSL Ltd
AU:CSL
Biotechnology 0.41%
Tango Therapeutics Inc
NASDAQ:TNGX
Biotechnology 57.90%
HLB Co. Ltd
KQ:028300
Biotechnology 0.72%
SOLENO THERAPEUT. DL-001
F:6XC
Biotechnology 41.74%
MBX Biosciences, Inc. Common Stock
NASDAQ:MBX
Biotechnology 87.20%
Tourmaline Bio Inc.
NASDAQ:TRML
Biotechnology 77.17%
PharmaResources (Shanghai) Co. Ltd. A
SHE:301230
Biotechnology 16.35%

Annual Asset Resilience Ratio for Hugel Inc (2014–2025)

The table below shows the annual Asset Resilience Ratio data for Hugel Inc.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2025-12-31 30.56% ₩329.07 Billion
≈ $223.01 Million
₩1.08 Trillion
≈ $729.76 Million
-14.48pp
2024-12-31 45.04% ₩423.12 Billion
≈ $286.74 Million
₩939.44 Billion
≈ $636.64 Million
-6.82pp
2023-12-31 51.86% ₩481.93 Billion
≈ $326.60 Million
₩929.25 Billion
≈ $629.74 Million
+1.95pp
2022-12-31 49.91% ₩523.99 Billion
≈ $355.10 Million
₩1.05 Trillion
≈ $711.42 Million
-4.77pp
2021-12-31 54.68% ₩552.13 Billion
≈ $374.17 Million
₩1.01 Trillion
≈ $684.28 Million
-7.98pp
2020-12-31 62.66% ₩599.20 Billion
≈ $406.07 Million
₩956.34 Billion
≈ $648.10 Million
-0.92pp
2019-12-31 63.58% ₩568.80 Billion
≈ $385.47 Million
₩894.69 Billion
≈ $606.32 Million
-1.93pp
2018-12-31 65.51% ₩601.56 Billion
≈ $407.67 Million
₩918.27 Billion
≈ $622.30 Million
-7.05pp
2017-12-31 72.56% ₩595.69 Billion
≈ $403.69 Million
₩820.93 Billion
≈ $556.33 Million
+37.19pp
2016-12-31 35.38% ₩104.11 Billion
≈ $70.55 Million
₩294.30 Billion
≈ $199.44 Million
+32.29pp
2015-12-31 3.08% ₩7.20 Billion
≈ $4.88 Million
₩233.57 Billion
≈ $158.29 Million
-9.54pp
2014-12-31 12.63% ₩12.28 Billion
≈ $8.32 Million
₩97.25 Billion
≈ $65.90 Million
--
pp = percentage points

About Hugel Inc

KQ:145020 Korea Biotechnology
Market Cap
$1.75 Billion
₩2.59 Trillion KRW
Market Cap Rank
#6764 Global
#178 in Korea
Share Price
₩239500.00
Change (1 day)
-3.43%
52-Week Range
₩214000.00 - ₩388000.00
All Time High
₩388000.00
About

Hugel, Inc. develops and manufactures biopharmaceuticals in South Korea and internationally. The company offers Botulinum Toxin, a white injectable dry powder in a transparent glass vial for use in the treatment of positive essential eyelid convulsion in adults over 18 years of age; improvement of severe lasso wrinkles associated with corrugator muscles and/or procerus muscle activities in adults… Read more